Aripiprazole
- Generic Name
- Aripiprazole
- Brand Names
- Abilify, Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen), Abilify Maintena, Aripiprazole Accord, Aripiprazole Sandoz, Aripiprazole Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27Cl2N3O2
- CAS Number
- 129722-12-9
- Unique Ingredient Identifier
- 82VFR53I78
- Background
Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A ...
- Indication
Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation as...
- Associated Conditions
- Agitation, Bipolar 1 Disorder, Irritability, Major Depressive Disorder (MDD), Mixed manic depressive episode, Psychosis, Psychotic Depression, Schizophrenia, Tourette's Disorder (TD), Acute Manic episode
- Associated Therapies
- Monotherapy
Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2018-06-12
- Target Recruit Count
- 36
- Registration Number
- NCT03150771
- Locations
- 🇺🇸
Community Clinical Research Inc., Austin, Texas, United States
🇺🇸CNRI-San Diego, San Diego, California, United States
🇺🇸Woodland International Research Group, Little Rock, Arkansas, United States
A Study of Diagnosis and Treatment of Depression Based on Biological Evidence of Dopamine Reward Pathway
- Conditions
- Interventions
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Peking University
- Target Recruit Count
- 300
- Registration Number
- NCT03148509
Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 3-year Follow-up
- Conditions
- Interventions
- First Posted Date
- 2017-03-24
- Last Posted Date
- 2019-07-10
- Lead Sponsor
- Fundación Marques de Valdecilla
- Target Recruit Count
- 200
- Registration Number
- NCT03090503
- Locations
- 🇪🇸
University Hospital Marques de Valdecilla, Santander, Cantabria, Spain
Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD
- Conditions
- Interventions
- First Posted Date
- 2016-11-30
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 278
- Registration Number
- NCT02977299
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸New York University, New York, New York, United States
🇺🇸Pacific Institute of Medical Research, Los Angeles, California, United States
Acceptance and Commitment Therapy in SSRI-Resistant Obsessive Compulsive Disorder
- Conditions
- Interventions
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- Shanghai Mental Health Center
- Registration Number
- NCT02955654
Aripiprazole as an Adjunct to Atypical Antipsychotics for Weight Reduction and Improvement in Metabolic Profile
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- Institute of Mental Health, Singapore
- Target Recruit Count
- 67
- Registration Number
- NCT02949752
- Locations
- 🇸🇬
Institute of Mental Health, Singapore, Singapore
Aripiprazole for Bipolar Disorder and Alcohol Use Disorder
- Conditions
- Interventions
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 132
- Registration Number
- NCT02918370
- Locations
- 🇺🇸
UT Southwestern, Dallas, Texas, United States
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
- Conditions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 1037352
- Registration Number
- NCT02893371
- Locations
- 🇺🇸
Christophe G Lambert, Albuquerque, New Mexico, United States
Aripiprazole, Abilify Maintena Collaborative Clinical Protocol
- First Posted Date
- 2016-03-23
- Last Posted Date
- 2020-04-13
- Lead Sponsor
- Florida Atlantic University
- Target Recruit Count
- 9
- Registration Number
- NCT02717130
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇺🇸University of Missouri, Kansas City, Missouri, United States
🇺🇸Burrell Behavioral Health, Springfield, Missouri, United States
The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment
- Conditions
- Interventions
- First Posted Date
- 2016-01-08
- Last Posted Date
- 2016-01-08
- Lead Sponsor
- Shanxi Medical University
- Target Recruit Count
- 200
- Registration Number
- NCT02650102
- Locations
- 🇨🇳
First Clinical Medical College of Shanxi Medical University, Taiyuan, Shanxi, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.